S1 Pharmaceuticals

S1 Biopharma is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class non-hormonal therapies for sexual dysfunction. The company's lead product candidate, Lorexys, is a fixed-dose combination of bupropion and trazodone currently in Phase 2 clinical trials for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD). By targeting the balance of dopamine, norepinephrine, and serotonin in the brain, S1 Biopharma aims to address the underlying neurobiology of sexual desire disorders. In addition to its focus on women's sexual health, the company is developing S1P-205 for male sexual dysfunction. S1 Biopharma leverages a proprietary approach to optimize the synergy between known CNS-active compounds to improve patient outcomes in underserved therapeutic areas.